These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32378446)

  • 1. Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.
    Fisch S; Bachner-Hinenzon N; Ertracht O; Guo L; Arad Y; Ben-Zvi D; Liao R; Schneiderman J
    J Am Heart Assoc; 2020 May; 9(10):e014761. PubMed ID: 32378446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.
    Hibender S; Franken R; van Roomen C; Ter Braake A; van der Made I; Schermer EE; Gunst Q; van den Hoff MJ; Lutgens E; Pinto YM; Groenink M; Zwinderman AH; Mulder BJ; de Vries CJ; de Waard V
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1618-26. PubMed ID: 27283746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-29b participates in early aneurysm development in Marfan syndrome.
    Merk DR; Chin JT; Dake BA; Maegdefessel L; Miller MO; Kimura N; Tsao PS; Iosef C; Berry GJ; Mohr FW; Spin JM; Alvira CM; Robbins RC; Fischbein MP
    Circ Res; 2012 Jan; 110(2):312-24. PubMed ID: 22116819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
    Verbrugghe P; Verhoeven J; Clijsters M; Vervoort D; Schepens J; Meuris B; Herijgers P
    J Cardiovasc Pharmacol; 2018 Apr; 71(4):215-222. PubMed ID: 29300219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated Marfan syndrome model recapitulates established signaling pathways.
    Gensicke NM; Cavanaugh NB; Andersen ND; Huang T; Qian L; Dyle MC; Turek JW
    J Thorac Cardiovasc Surg; 2020 May; 159(5):1719-1726. PubMed ID: 31272746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Benefits of Moderate Exercise Training in Marfan Syndrome: Insights From an Animal Model.
    Mas-Stachurska A; Siegert AM; Batlle M; Gorbenko Del Blanco D; Meirelles T; Rubies C; Bonorino F; Serra-Peinado C; Bijnens B; Baudin J; Sitges M; Mont L; Guasch E; Egea G
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28947563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aortopathy in a Mouse Model of Marfan Syndrome Is Not Mediated by Altered Transforming Growth Factor β Signaling.
    Wei H; Hu JH; Angelov SN; Fox K; Yan J; Enstrom R; Smith A; Dichek DA
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28119285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular characteristics in Marfan syndrome and their relation to the genotype.
    De Backer J
    Verh K Acad Geneeskd Belg; 2009; 71(6):335-71. PubMed ID: 20232788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogenesis of aortic wall complications in Marfan syndrome.
    Grewal N; Gittenberger-de Groot AC
    Cardiovasc Pathol; 2018; 33():62-69. PubMed ID: 29433109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal cystic disease in the Fbn1
    Hibender S; Wanga S; van der Made I; Vos M; Mulder BJ; Balm R; de Vries CJ; de Waard V
    Cardiovasc Pathol; 2019; 38():1-6. PubMed ID: 30359839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
    Mallat Z; Daugherty A
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhanced caspase activity contributes to aortic wall remodeling and early aneurysm development in a murine model of Marfan syndrome.
    Emrich FC; Okamura H; Dalal AR; Penov K; Merk DR; Raaz U; Hennigs JK; Chin JT; Miller MO; Pedroza AJ; Craig JK; Koyano TK; Blankenberg FG; Connolly AJ; Mohr FW; Alvira CM; Rabinovitch M; Fischbein MP
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):146-54. PubMed ID: 25359856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Notch3 Activation on Aortic Aneurysm Development in Marfan Syndrome.
    Jespersen K; Li C; Batra R; Stephenson CA; Harding P; Sestak K; Foley RT; Greene H; Meisinger T; Cook JR; Baxter BT; Xiong W
    J Immunol Res; 2022; 2022():7538649. PubMed ID: 35211631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics reveals Rictor as a noncanonical TGF-β signaling target during aneurysm progression in Marfan mice.
    Parker SJ; Stotland A; MacFarlane E; Wilson N; Orosco A; Venkatraman V; Madrid K; Gottlieb R; Dietz HC; Van Eyk JE
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1112-H1126. PubMed ID: 30004239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Cell Transcriptomic Profiling of Vascular Smooth Muscle Cell Phenotype Modulation in Marfan Syndrome Aortic Aneurysm.
    Pedroza AJ; Tashima Y; Shad R; Cheng P; Wirka R; Churovich S; Nakamura K; Yokoyama N; Cui JZ; Iosef C; Hiesinger W; Quertermous T; Fischbein MP
    Arterioscler Thromb Vasc Biol; 2020 Sep; 40(9):2195-2211. PubMed ID: 32698686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology of aortic complications in bicuspid aortic valve versus Marfan syndrome: relevance for therapy?
    Grewal N; Franken R; Mulder BJ; Goumans MJ; Lindeman JH; Jongbloed MR; DeRuiter MC; Klautz RJ; Bogers AJ; Poelmann RE; Groot AC
    Heart Vessels; 2016 May; 31(5):795-806. PubMed ID: 26129868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm.
    Jiménez-Altayó F; Meirelles T; Crosas-Molist E; Sorolla MA; Del Blanco DG; López-Luque J; Mas-Stachurska A; Siegert AM; Bonorino F; Barberà L; García C; Condom E; Sitges M; Rodríguez-Pascual F; Laurindo F; Schröder K; Ros J; Fabregat I; Egea G
    Free Radic Biol Med; 2018 Apr; 118():44-58. PubMed ID: 29471108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Local Application of Leptin Antagonist Attenuates Angiotensin II-Induced Ascending Aortic Aneurysm and Cardiac Remodeling.
    Ben-Zvi D; Savion N; Kolodgie F; Simon A; Fisch S; Schäfer K; Bachner-Hinenzon N; Cao X; Gertler A; Solomon G; Kachel E; Raanani E; Lavee J; Kotev Emeth S; Virmani R; Schoen FJ; Schneiderman J
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27143353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimorphic effects of transforming growth factor-β signaling during aortic aneurysm progression in mice suggest a combinatorial therapy for Marfan syndrome.
    Cook JR; Clayton NP; Carta L; Galatioto J; Chiu E; Smaldone S; Nelson CA; Cheng SH; Wentworth BM; Ramirez F
    Arterioscler Thromb Vasc Biol; 2015 Apr; 35(4):911-7. PubMed ID: 25614286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.